Scott Gettinger
Impact in
- Oncology top 0.05%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- CAR-T cell therapy research
- Colorectal Cancer Treatments and Studies
- Pulmonary and Respiratory Medicine top 0.1%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
- Oncology 214
- Cancer Immunotherapy and Biomarkers 124
- Lung Cancer Research Studies 66
- Colorectal Cancer Treatments and Studies 49
- CAR-T cell therapy research 22
- Peptidase Inhibition and Analysis 16
-
- Lung Cancer Treatments and Mutations 161
- Lung Cancer Diagnosis and Treatment 38
- Co-authors
- Scott Antonia (47 shared papers)Roy S. Herbst (41 shared papers)Julie R. Brahmer (46 shared papers)Laura Q.M. Chow (38 shared papers)Kurt A. Schalper (19 shared papers)Naiyer A. Rizvi (31 shared papers)Hossein Borghaei (30 shared papers)David L. Rimm (15 shared papers)
- Journals
- Journal of Clinical Oncology (92 papers)Annals of Oncology (34 papers)Journal of Thoracic Oncology (29 papers)International Journal of Radiation Oncology*Biology*Physics (12 papers)Clinical Cancer Research (9 papers)
- Partner nations
- United StatesSpainItaly
In The Last Decade
Scott Gettinger
253 papers receiving 13.0k citations
Scott Gettinger's Hit Papers
Peers
Comparison fields: 5 of 128
- Oncology 10.3k
- Pulmonary and Respiratory Medicine 6.8k
- Immunology 2.8k
- Cancer Research 1.7k
- Genetics 471
Countries citing papers authored by Scott Gettinger
This map shows the geographic impact of Scott Gettinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott Gettinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott Gettinger more than expected).
Fields of papers citing papers by Scott Gettinger
This network shows the impact of papers produced by Scott Gettinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott Gettinger. The network helps show where Scott Gettinger may publish in the future.
Co-authors
The 25 scholars most cited alongside Scott Gettinger, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 258 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study Hit paper breakdown → | 2016 | 700 |
| 2 | Programmed death ligand-1 expression in non-small cell lung cancer Hit paper breakdown → | 2013 | 652 |
| 3 | Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study Hit paper breakdown → | 2018 | 539 |
| 4 | Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial Hit paper breakdown → | 2017 | 430 |
| 5 | Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors Hit paper breakdown → | 2018 | 412 |
| 6 | Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab Hit paper breakdown → | 2019 | 409 |
| 7 | Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer Hit paper breakdown → | 2016 | 394 |
| 8 | Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer Hit paper breakdown → | 2016 | 350 |
| 9 | 2014 | 322 | |
| 10 | Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA Hit paper breakdown → | 2018 | 317 |
| 11 | 2014 | 295 | |
| 12 | 2010 | 263 | |
| 13 | 2016 | 261 | |
| 14 | 2019 | 238 | |
| 15 | 2018 | 235 | |
| 16 | 2019 | 225 | |
| 17 | 2016 | 213 | |
| 18 | 2016 | 177 | |
| 19 | 2014 | 154 | |
| 20 | 2017 | 151 |
About Scott Gettinger
Scott Gettinger is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology and Immunology, having authored 258 papers that have together received 13.2k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (161 papers), Cancer Immunotherapy and Biomarkers (124 papers), Lung Cancer Research Studies (66 papers), Colorectal Cancer Treatments and Studies (49 papers), Cancer Genomics and Diagnostics (40 papers), Lung Cancer Diagnosis and Treatment (38 papers), CAR-T cell therapy research (22 papers) and Peptidase Inhibition and Analysis (16 papers). The work is most often cited by research in Oncology (10.3k citations), Pulmonary and Respiratory Medicine (6.8k citations), Immunology (2.8k citations), Cancer Research (1.7k citations) and Genetics (471 citations). Scott Gettinger has collaborated with scholars based in United States, Spain and Italy. Frequent co-authors include Scott Antonia, Roy S. Herbst, Julie R. Brahmer, Laura Q.M. Chow, Kurt A. Schalper, Naiyer A. Rizvi, Hossein Borghaei, David L. Rimm, Matthew D. Hellmann and Mario Sznol. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of Thoracic Oncology, International Journal of Radiation Oncology*Biology*Physics and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.